Ikarian Capital, LLC Inventiva S.A. Call Options Transaction History
Ikarian Capital, LLC
- $606 Million
- Q4 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|---|---|---|---|---|
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding IVA
# of Institutions
7Shares Held
5.45MCall Options Held
0Put Options Held
0-
Yiheng Capital Management, L.P. San Francisco, CA2.64MShares$6.64 Million0.23% of portfolio
-
Nea Management Company, LLC Timonium, MD1.46MShares$3.67 Million0.22% of portfolio
-
Bvf Inc San Francisco, CA686KShares$1.72 Million0.05% of portfolio
-
Ubs Group Ag609KShares$1.53 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC42KShares$105,4170.0% of portfolio
About Inventiva S.A.
- Ticker IVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,134,200
- Market Cap $106M
- Description
- Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...